Stocks and Investing
Stocks and Investing
Wed, February 21, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Ami Fadia Reiterated (BCYC) at Strong Buy and Held Target at $43 on, Feb 21st, 2024
Ami Fadia of Needham, Reiterated "Bicycle Therapeutics plc" (BCYC) at Strong Buy and Held Target at $43 on, Feb 21st, 2024.
Ami has made no other calls on BCYC in the last 4 months.
There are 3 other peers that have a rating on BCYC. Out of the 3 peers that are also analyzing BCYC, 1 agrees with Ami's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Decreased Target to $40 on, Friday, November 3rd, 2023
These are the ratings of the 2 analyists that currently disagree with Ami
- Reni Benjamin of "JMP Securities" Maintained at Buy with Decreased Target to $32 on, Wednesday, December 20th, 2023
- Li Watsek of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $65 on, Wednesday, November 8th, 2023
Contributing Sources